We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

BPCIA At Fed. Circ.: Awaiting Guidance On Patent Dance

Law360, New York (October 12, 2017, 1:27 PM EDT) -- On Oct. 2, 2017, a Federal Circuit panel consisting of Judges Kathleen O’Malley, Alan Lourie and Richard Taranto heard arguments in Amgen v. Apotex (17-1010), which involved Apotex’s Neulasta and Neupogen biosimilars that have yet to be approved by the U.S. Food and Drug Administration.

Filed October 2015 in the Southern District of Florida, Amgen v. Apotex was the first Biologics Price Competition and Innovation Act litigation to conclude on the merits (as opposed to settlement or jurisdictional rulings). The district court found that Apotex’s biosimilar manufacturing processes did...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.